Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are studying the pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in children aged 5 to under 18 years with moderate to severe systemic lupus erythematosus SLE who are receiving standard of care treatments. This open-label, multicenter Phase II study aims to understand how the medication behaves in the body and its effects in this pediatric population. The study includes screening for up to 35 days followed by a 12-week treatment period where anifrolumab is given as a subcutaneous injection using an accessorized pre-filled syringe. There is an optional 12-week period to adjust the dosing regimen if needed, and participants may enter an optional treatment extension lasting up to 40 weeks. After treatment, a 12-week safety follow-up period is conducted. Participants are grouped into two cohorts based on body weight those weighing more than 40 kg and those between 15 and 40 kg, both receiving the study drug via injection. Participants will undergo various assessments including blood tests to measure drug levels and immune response markers at multiple time points, especially during the first days and up to week 12. Researchers will monitor safety and immune system activity through laboratory tests and clinical evaluations throughout the study and follow-up periods. The total duration of participation may extend over several months depending on whether participants enter the extension period, allowing detailed observation of treatment effects and safety.